A New Look on an Old Issue: Comprehensive Review of Neurotransmitter Studies in Cerebrospinal Fluid of Patients with Schizophrenia and Antipsychotic Effect on Monoamine’s Metabolism

키워드

참고문헌 (88)

1. Owen MJ, "Schizophrenia", Lancet, 388, pp.86~97 (2016)
2. Howes OD, "Treatment-resistant schizophrenia : Treatment Response and Resistance in Psychosis(TRRIP)working group consensus guidelines on diagnosis and terminology", Am J Psychiatry, 174, pp.216~229 (2017)
3. Delay J, "Neuroleptic effects of chlorpromazine in therapeutics of neuropsychiatry", Int Rec Med Gen Pract Clin, 168, pp.318~326 (1955)
4. Millan MJ, "Altering the course of schizophrenia : progress and perspectives", Nat Rev Drug Discov, 15, pp.485~515 (2016)
5. Birnbaum R, "Genetic insights into the neurodevelopmental origins of schizophrenia", Nat Rev Neurosci, 18, pp.727~740 (2017)
6. Schizophrenia Working Group of the Psychiatric Genomics Consortium, "Biological insights from 108 schizophrenia-associated genetic loci", Nature, 511, pp.421~427 (2014)
7. Smeland OB, "The polygenic architecture of schizophrenia-rethinking pathogenesis and nosology", Nat Rev Neurol, 16, pp.366~379 (2020)
8. Grace AA, "Dysregulation of the dopamine system in the pathophysiology of schizophrenia and depression", Nat Rev Neurosci, 17, pp.524~532 (2016)
9. Jauhar S, "The effects of antipsychotic treatment on presynaptic dopamine synthesis capacity in first-episode psychosis : a positron emission tomography study", Biol Psychiatry, 85, pp.79~87 (2019)
10. Hardingham GE, "Linking early-life NMDAR hypofunction and oxidative stress in schizophrenia pathogenesis", Nat Rev Neurosci, 17, pp.125~134 (2016)
11. Stahl SM, "Stahl’s essential psychopharmacology: neuroscientific basis and practical applications", pp.625~ (2013), Cambridge University Press
12. Ramaekers VT, "Folinic acid treatment for schizophrenia associated with folate receptor autoantibodies", Mol Genet Metab, 113, pp.307~314 (2014)
13. Fryar-Williams S, "Fundamental role of methylenetetrahydrofolate reductase 677 C → T genotype and flavin compounds in biochemical phenotypes for schizophrenia and schizoaffective psychosis", Front Psychiatry, 7, pp.172~ (2016)
14. Wan L, "Methylenetetrahydrofolate reductase and psychiatric diseases", Transl Psychiatry, 8, pp.242~ (2018)
15. Moustafa AA, "Homocysteine levels in schizophrenia and affective disorders-focus on cognition", Front Behav Neurosci, 8, pp.343~ (2014)
16. Müller N, "Inflammation in schizophrenia : pathogenetic aspects and therapeutic considerations", Schizophr Bull, 44, pp.973~982 (2018)
17. Vinckier F, "Confidence and psychosis : a neuro-computational account of contingency learning disruption by NMDA blockade", Mol Psychiatry, 21, pp.946~955 (2016)
18. Orlovska-Waast S, "Cerebrospinal fluid markers of inflammation and infections in schizophrenia and affective disorders : a systematic review and meta-analysis", Mol Psychiatry, 24, pp.869~887 (2019)
19. Juncal-Ruiz M, "Comparison of the anti-inflammatory effect of aripiprazole and risperidone in 75 drug-naïve first episode psychosis individuals : a 3 months randomized study", Schizophr Res, 202, pp.226~233 (2018)
20. Borovcanin MM, "Interleukin-6 in schizophrenia- is there a therapeutic relevance?", Front Psychiatry, 8, pp.221~ (2017)
21. Ellul P, "Regulatory T cells As supporters of psychoimmune resilience : toward immunotherapy of major depressive disorder", Front Neurol, 9, pp.167~ (2018)
22. Plitman E, "Kynurenic acid in schizophrenia : a systematic review and meta-analysis", Schizophr Bull, 43, pp.764~777 (2017)
23. Scheinin M, "Determination of conjugated dopamine in cerebrospinal fluid from humans and non-human primates with high performance liquid chromatography using electrochemical detection", Acta Pharmacol Toxicol(Copenh), 55, pp.88~94 (1984)
24. Davis KL, "Dopamine in schizophrenia : a review and reconceptualization", Am J Psychiatry, 148, pp.1474~1486 (1991)
25. Berger PA, "CSF monoamine metabolites in depression and schizophrenia", Am J Psychiatry, 137, pp.174~180 (1980)
26. Nybäck H, "Cerebroventricular size and cerebrospinal fluid monoamine metabolites in schizophrenic patients and healthy volunteers", Psychiatry Res, 9, pp.301~308 (1983)
27. Bjerkenstedt L, "Plasma amino acids in relation to cerebrospinal fluid monoamine metabolites in schizophrenic patients and healthy controls", Br J Psychiatry, 147, pp.276~282 (1985)
28. Miller C, "CSF of neuroleptic-naive first-episode schizophrenic patients : levels of biogenic amines, substance P, and peptides derived from chromogranin A(GE-25)and secretogranin II(secretoneurin)", Biol Psychiatry, 39, pp.911~918 (1996)
29. Lindström LH, "Low HVA and normal 5HIAA CSF levels in drug-free schizophrenic patients compared to healthy volunteers : correlations to symptomatology and family history", Psychiatry Res, 14, pp.265~273 (1985)
30. Wieselgren IM, "CSF levels of HVA and 5-HIAA in drug-free schizophrenic patients and healthy controls : a prospective study focused on their predictive value for outcome in schizophrenia", Psychiatry Res, 81, pp.101~110 (1998)
31. Nikkilä HV, "Neopterin and macrophage inflammatory protein-1alpha in the cerebrospinal fluid of schizophrenic patients : no evidence of intrathecal inflammation", Neuropsychobiology, 46, pp.169~172 (2002)
32. Lewine RR, "Lateral ventricle-brain ratio and balance between CSF HVA and 5-HIAA in schizophrenia", Am J Psychiatry, 148, pp.1189~1194 (1991)
33. Houston JP, "Cerebrospinal fluid HVA, central brain atrophy, and clinical state in schizophrenia", Psychiatry Res, 19, pp.207~214 (1986)
34. Jennings WS Jr, "Brain ventricular size and CSF monoamine metabolites in an adolescent inpatient population", Psychiatry Res, 16, pp.87~94 (1985)
35. Post RM, "Time-dependent effects of phenothiazines on dopamine turnover in psychiatric patients", Science, 190, pp.488~489 (1975)
36. Anand I, "Csf amines and their metabolites in first episode drug naive schizophrenic patients and their correlations with dimensions of schizophrenia", Indian J Psychiatry, 44, pp.212~219 (2002)
37. Neider D, "Risk factors for suicide among patients with schizophrenia : a cohort study focused on cerebrospinal fluid levels of homovanillic acid and 5-hydroxyindoleacetic acid", Neuropsychiatr Dis Treat, 12, pp.1711~1714 (2016)
38. Pickar D, "Clinical and biologic response to clozapine in patients with schizophrenia. Crossover comparison with fluphenazine", Arch Gen Psychiatry, 49, pp.345~353 (1992)
39. Szymanski S, "The dopamine-serotonin relationship in clozapine response", Psychopharmacology (Berl), 112(1 Suppl), pp.S85~S89 (1993)
40. Risch SC, "Low cerebrospinal fluid homovanillic acid-5-hydroxyindoleacetic acid ratio predicts clozapine efficacy : a replication", Arch Gen Psychiatry, 50, pp.670~ (1993)
41. Samanaite R, "Biological predictors of clozapine response : a systematic review", Front Psychiatry, 9, pp.327~ (2018)
42. Kahn RS, "Effect of neuroleptic medication on cerebrospinal fluid monoamine metabolite concentrations in schizophrenia. Serotonindopamine interactions as a target for treatment", Arch Gen Psychiatry, 50, pp.599~605 (1993)
43. Sharma RP, "Homovanillic acid in the cerebrospinal fluid : patterns of response after four weeks of neuroleptic treatment", Biol Psychiatry, 34, pp.128~134 (1993)
44. Nikisch G, "Quetiapine and norquetiapine in plasma and cerebrospinal fluid of schizophrenic patients treated with quetiapine : correlations to clinical outcome and HVA, 5-HIAA, and MHPG in CSF", J Clin Psychopharmacol, 30, pp.496~503 (2010)
45. Schwarcz R, "Increased cortical kynurenate content in schizophrenia", Biol Psychiatry, 50, pp.521~530 (2001)
46. Erhardt S, "Kynurenic acid levels are elevated in the cerebrospinal fluid of patients with schizophrenia", Neurosci Lett, 313, pp.96~98 (2001)
47. Nilsson LK, "Elevated levels of kynurenic acid in the cerebrospinal fluid of male patients with schizophrenia", Schizophr Res, 80, pp.315~322 (2005)
48. Linderholm KR, "Increased levels of kynurenine and kynurenic acid in the CSF of patients with schizophrenia", Schizophr Bull, 38, pp.426~432 (2012)
49. Chang WH, "Dose-response curves of homovanillic acid in pre-frontal cortex and caudate following antipsychotic drugs: relation to clinical potencies", Psychopharmacology(Berl), 95, pp.459~462 (1988)
50. Stawarz RJ, "On the significance of the increase in homovanillic acid(HVA)caused by antipsychotic drugs in corpus striatum and limbic forebrain", Psychopharmacologia, 43, pp.125~130 (1975)
51. Pugsley TA, "Effect of structural analogs of butaclamol(a new antipsychotic drug)on striatal homovanillic acid and adenyl cyclase of olfactory tubercle in rats", Can J Physiol Pharmacol, 54, pp.510~515 (1976)
52. Wiesel FA, "Effect of antipsychotic drugs on homovanillic acid levels in striatum and olfactory tubercle of the rat", Eur J Pharmacol, 30, pp.364~367 (1975)
53. Bowers MB Jr, "Dopamine metabolites and catalepsy after lithium and haloperidol", Eur J Pharmacol, 78, pp.113~115 (1982)
54. Rastogi RB, "Comparative effects of short-and long-term treatment with neuroleptics on behavioural activity as well as dopamine turnover in striatum", Gen Pharmacol, 13, pp.35~40 (1982)
55. Scatton B, "Effect of single and repeated administration of haloperidol and sulpiride on striatal and retinal dopamine turnover in the rat", Brain Res, 135, pp.374~377 (1977)
56. Bowers MB Jr, "Homovanillic acid in caudate and pre-frontal cortex following neuroleptics", Eur J Pharmacol, 99, pp.103~105 (1984)
57. Bowers MB Jr, "Homovanillic acid in caudate and pre-frontal cortex following acute and chronic neuroleptic administration", Psychopharmacology(Berl), 88, pp.63~65 (1986)
58. Watanabe M, "The atypical antipsychotic sertindole enhances efflux of dopamine and its metabolites in the rat cortex and striatum", Eur J Pharmacol, 367, pp.19~23 (1999)
59. Antoniou K, "The effects of antipsychotic drugs on serotonergic activity in the rat hippocampus", Eur Neuropsychopharmacol, 10, pp.315~324 (2000)
60. Jordan S, "In vivo effects of aripiprazole on cortical and striatal dopaminergic and serotonergic function", Eur J Pharmacol, 483, pp.45~53 (2004)
61. Arjona AA, "An animal model of antipsychotic-induced weight gain", Behav Brain Res, 152, pp.121~127 (2004)
62. Hernandez L, "Chronic clozapine selectively decreases prefrontal cortex dopamine as shown by simultaneous cortical, accumbens, and striatal microdialysis in freely moving rats", Pharmacol Biochem Behav, 52, pp.581~589 (1995)
63. Haleem DJ, "Differences in the effects of haloperidol and clozapine on brain serotonin and dopamine metabolism and on tests related to extrapyramidal functions in rats", Med Sci Monit, 8, pp.BR354~BR361 (2002)
64. Clow A, "Changes in rat striatal dopamine turnover and receptor activity during one years neuroleptic administration", Eur J Pharmacol, 63, pp.135~144 (1980)
65. Nicolaou NM, "Acute and chronic effects of neuroleptics and acute effects of apomorphine and amphetamine on dopamine turnover in corpus striatum and substantia nigra of the rat brain", Eur J Pharmacol, 64, pp.123~132 (1980)
66. Mefford IN, "Enhancement of dopamine metabolism in rat brain frontal cortex : a common effect of chronically administered antipsychotic drugs", Brain Res, 475, pp.380~384 (1988)
67. Shannak KS, "Brain monoamines in the rhesus monkey during long-term neuroleptic administration", Adv Biochem Psychopharmacol, 24, pp.315~323 (1980)
68. Gunne LM, "Experimental tardive dyskinesia", J Clin Psychiatry, 46(4 Pt 2), pp.48~50 (1985)
69. Bowers MB Jr, "Brain homovanillic acid : regional changes over time with antipsychotic drugs", Eur J Pharmacol, 39, pp.109~115 (1976)
70. See RE, "Regional differences in chronic neuroleptic effects on extracellular dopamine activity", Brain Res Bull, 29, pp.473~478 (1992)
71. Sedvall G, "Mass fragmentometric determination of homovanillic acid in lumbar cerebrospinal fluid of schizophrenic patients during treatment with antipsychotic drugs", J Psychiatr Res, 11, pp.75~80 (1974)
72. Rüther E, "Clinical and biochemical parameters during neuroleptic treatment. I. Investigations with haloperidol", Pharmakopsychiatr Neuropsychopharmakol, 9, pp.33~36 (1976)
73. Wode-Helgodt B, "Effect of chlorpromazine treatment on prolactin levels in cerebrospinal fluid and plasma of psychotic patients", Acta Psychiatr Scand, 56, pp.280~293 (1977)
74. Doran AR, "Fluphenazine treatment reduces CSF somatostatin in patients with schizophrenia : correlations with CSF HVA", Biol Psychiatry, 25, pp.431~439 (1989)
75. Sharma R, "Plasma and CSF HVA before and after pharmacological treatment", Psychiatry Res, 28, pp.97~104 (1989)
76. Alfredsson G, "Relationships between drug concentrations in serum and CSF, clinical effects and monoaminergic variables in schizophrenic patients treated with sulpiride or chlorpromazine", Acta Psychiatr Scand Suppl, 311, pp.49~74 (1984)
77. Härnryd C, "Time course for effects of sulpiride and chlorpromazine on monoamine metabolite and prolactin levels in cerebrospinal fluid from schizophrenic patients", Acta Psychiatr Scand Suppl, 311, pp.75~92 (1984)
78. Scheepers FE, "The effect of olanzapine treatment on monoamine metabolite concentrations in the cerebrospinal fluid of schizophrenic patients", Neuropsychopharmacology, 25, pp.468~475 (2001)
79. Gerlach J, "Extrapyramidal reactions and amine metabolites in cerebrospinal fluid during haloperidol and clozapine treatment of schizophrenic patients", Psychopharmacologia, 40, pp.341~350 (1975)
80. Bagdy G, "Decrease of CSF dopamine, its metabolites and noradrenalin after withdrawal of chronic neuroleptic treatment in schizophrenic patients", Psychiatry Res, 12, pp.177~178 (1984)
81. Perényi A, "Changes in mental condition, hyperkinesias and biochemical parameters after withdrawal of chronic neuroleptic treatment", Acta Psychiatr Scand, 72, pp.430~435 (1985)
82. Pickar D, "Perspectives on a time-dependent model of neuroleptic action", Schizophr Bull, 14, pp.255~268 (1988)
83. Frecska E, "CSF dopamine turnover and positive schizophrenic symptoms after withdrawal of long-term neuroleptic treatment", Psychiatry Res, 16, pp.221~226 (1985)
84. Beuger M, "Dopamine turnover in schizophrenia before and after haloperidol withdrawal. CSF, plasma, and urine studies", Neuropsychopharmacology, 15, pp.75~86 (1996)
85. Verbeek MM, "Technical and biochemical factors affecting cerebrospinal fluid 5-MTHF, biopterin and neopterin concentrations", Mol Genet Metab, 95, pp.127~132 (2008)
86. Cahn W, "Brain volume changes in the first year of illness and 5-year outcome of schizophrenia", Br J Psychiatry, 189, pp.381~382 (2006)
87. Wester P, "Ventricular cerebrospinal fluid monoamine transmitter and metabolite concentrations reflect human brain neurochemistry in autopsy cases", J Neurochem, 54, pp.1148~1156 (1990)
88. Eklundh T, "Monoamine precursors, transmitters and metabolites in cerebrospinal fluid : a prospective study in healthy male subjects", J Psychiatr Res, 30, pp.201~208 (1996)

관련 논문AI추천